Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sylvia Garny"'
Autor:
Sebastian H. Maier, Stephan Schönecker, Vasiliki Anagnostatou, Sylvia Garny, Alexander Nitschmann, Daniel F. Fleischmann, Marcel Büttner, David Kaul, Detlef Imhoff, Emmanouil Fokas, Clemens Seidel, Peter Hau, Oliver Kölbl, Ilinca Popp, Anca-Ligia Grosu, Jan Haussmann, Wilfried Budach, Eren Celik, Klaus-Henning Kahl, Elgin Hoffmann, Ghazaleh Tabatabai, Frank Paulsen, Adrien Holzgreve, Nathalie L. Albert, Ulrich Mansmann, Stefanie Corradini, Claus Belka, Maximilian Niyazi, Raphael Bodensohn
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 47, Iss , Pp 100790- (2024)
Background: The PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06; NCT05871021) is designed to determine whether a dose escalation with 75.0 Gy in 30 fractions can enhance the median overall survival (OS) in patients with methylguanine methyltransferase (M
Externí odkaz:
https://doaj.org/article/e593b5076b1b4d3582a15845aa79e307
Autor:
Raphael Bodensohn, Daniel F. Fleischmann, Sebastian H. Maier, Vasiliki Anagnostatou, Sylvia Garny, Alexander Nitschmann, Marcel Büttner, Johannes Mücke, Stephan Schönecker, Kristian Unger, Elgin Hoffmann, Frank Paulsen, Daniela Thorwarth, Adrien Holzgreve, Nathalie L. Albert, Stefanie Corradini, Ghazaleh Tabatabai, Claus Belka, Maximilian Niyazi
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 45, Iss , Pp 100706- (2024)
Background and purpose: The PRIDE trial (NOA-28; ARO-2022-12; NCT05871021) is scheduled to start recruitment in October 2023. Its primary objective is to enhance median overall survival (OS), compared to historical median OS rates, in patients with m
Externí odkaz:
https://doaj.org/article/2e39a454d584431f845c26def0ecbd15
Autor:
Jan Hofmaier, Raphael Bodensohn, Sylvia Garny, Indrawati Hadi, Daniel F. Fleischmann, Michael Eder, Yavuz Dinc, Michael Reiner, Stefanie Corradini, Katia Parodi, Claus Belka, Maximilian Niyazi
Publikováno v:
Radiation Oncology, Vol 14, Iss 1, Pp 1-8 (2019)
Abstract Background In this dosimetric study, a dedicated planning tool for single isocenter stereotactic radiosurgery for multiple brain metastases using dynamic conformal arc therapy (DCAT) was compared to standard volumetric modulated arc therapy
Externí odkaz:
https://doaj.org/article/9bfe584c12ee4d4c85dc930bc0c627b3